Preview Mode Links will not work in preview mode

JACC Journals podcasts deliver expert insights and key takeaways from the latest cardiovascular science. Hosted by Editor-in-Chief Harlan M. Krumholz, MD, SM, JACC This Week offers engaging summaries and commentary from each weekly issue, complemented by a growing library of deep-dive interviews, global perspectives, and author conversations that highlight the research and innovation shaping cardiovascular medicine worldwide.

  1. All Episodes
  2. March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inhibitors & What Improvement Really Means | JACC This Week

March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inhibitors & What Improvement Really Means | JACC This Week

Mar 3, 2026

In this episode of JACC This Week, Dr. Carolyn Lam and Dr. Harlan Krumholz spotlight a mini-focus issue on hypertrophic cardiomyopathy (HCM), a field undergoing rapid transformation.
The discussion centers on the MAPLE-HCM trial comparing aficamten and metoprolol in symptomatic obstructive HCM, highlighting multidomain response analysis and what it means to measure meaningful improvement. Beyond gradients and biomarkers, the conversation explores a critical question: when physiologic surrogates improve, how should we interpret patient-centered outcomes?
Framed by the Editor’s Page, “What Does Improvement Mean?”, this episode examines the evolving role of myosin inhibitors, disease modification, and the tension between surrogate markers and real-world clinical benefit.
Additional highlights include disaggregation of Asian ethnicities in heart failure quality-of-care research and emerging evidence on AI-driven ECG models to predict incident heart failure—underscoring JACC’s commitment to precision, equity, and innovation.
This issue reflects a broader shift across cardiology: transforming once-static diseases into treatable chronic conditions guided by rigorous evidence.